Generic Drugs Stocks on Investors' Radar -- Akorn, Collegium Pharma, Momenta Pharma, and Diplomat Pharma

Wednesday, June 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 28, 2017 /PRNewswire/ --

If you want a Stock Review on AKRX, COLL, MNTA or DPLO then come over to and sign up for your free customized report today. On Tuesday, June 27, 2017, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in
red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,146.62, down 1.61%; the Dow Jones Industrial Average edged 0.46% lower, to finish at 21,310.66; and the S&P 500 closed at 2,419.38, down 0.81%. This Wednesday morning, looks at the performance of these four Drugs - Generic stocks: Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Diplomat Pharmacy Inc. (NYSE: DPLO). This morning's free research reports on the aforesaid equities can be accessed upon registration on at:


Lake Forest, Illinois headquartered Akorn Inc.'s stock finished Tuesday's session 0.51% lower at $33.41 with a total trading volume of 1.11 million shares. The Company's shares have advanced 0.60% in the past month, 34.88% over the previous three months, and 53.05% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.57% and 29.43%, respectively. Furthermore, shares of Akorn, which develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the US and internationally, have a Relative Strength Index (RSI) of 50.37. Visit us today and download your complete report on AKRX for free at:

Collegium Pharma 

Shares in Canton, Massachusetts headquartered Collegium Pharmaceutical Inc. ended at $12.36, down 5.07% from the last trading session. The stock recorded a trading volume of 490,870 shares, which was above its three months average volume of 439,740 shares. The Company's shares have gained 40.45% in the last one month and 6.55% in the previous three months. The stock is trading 27.25% above its 50-day moving average. Moreover, shares of Collegium Pharma, which develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases, have an RSI of 66.13. The complimentary research report on COLL can be accessed at:

Momenta Pharma 

Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock ended yesterday's session 2.48% lower at $17.70 with a total trading volume of 519,503 shares. The Company's shares have advanced 20.00% in the past month, 31.60% over the previous three months, and 17.61% on an YTD basis. The stock is trading 15.04% and 22.89% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 66.07. Register for free on and download the research report on MNTA at:

Diplomat Pharma 

On Tuesday, shares in Flint, Michigan headquartered Diplomat Pharmacy Inc. recorded a trading volume of 2.17 million shares, which was above their three months average volume of 680,610 shares. The stock finished 7.33% lower at $15.30. The Company's shares have advanced 21.43% since the start of this year. The stock is trading below its 50-day moving average by 10.90%. Furthermore, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 31.09. Get free access to your research report on DPLO at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store